Antibodies against myelin oligodendrocyte glycoprotein in the cerebrospinal fluid of multiple sclerosis patients

Journal of the Neurological Sciences

Volumn 211, Issue 1-2, 2003, Pages 67-73

  Markovic, Milos ^a   Trajkovic, Vladimir ^a   Drulovic, Jelena ^a   Mesaros, Sarlota ^a   Stojsavljevic, Nebojsa ^a   Dujmovic, Irena ^a   Stojkovic, Marija Mostarica ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Antibodies; Cerebrospinal fluid; Disease activity; Multiple sclerosis; Myelin oligodendrocyte glycoprotein; Neurosarcoidosis

Indexed keywords

MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PROTEIN ANTIBODY;

ADULT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOPATHOGENESIS; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SARCOIDOSIS;

EID: 0038290605     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(03)00066-2     Document Type: Article

References (42)

1. Brosnan C.F., Raine C.S. Mechanisms of immune injury in multiple sclerosis. Brain Pathol. 6:1996;243-257.
2. Lucchinetti C.F., Bruck W., Rodriguez M., Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol. 6:1996;259-274.
3. Archelos J.J., Storch M.K., Hartung H.-P. The role of B cells and autoantibodies in multiple sclerosis. Ann. Neurol. 47:2000;694-706.
4. Linington C., Webb M., Woodhams P.L. A novel myelin-associated glycoprotein defined by a mouse monoclonal antibody. J. Neuroimmunol. 6:1984;387-396.
5. Brunner C., Lassmann H., Waehneldt T.V., Matthieu J.M., Linington C. Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2′,3′-cyclic nucleotide 3′-phosphodiesterase in the CNS of adult rats. J. Neurochem. 52:1989;296-304.
6. Gardinier M.V., Amiguet P., Linington C., Matthieu J.M. Myelin/oligodendrocyte glycoprotein is a unique member of the immunoglobulin superfamily. J. Neurosci. Res. 33:1992;177-187.
7. Kroepfl J.F., Viise L.R., Charron A.J., Linington C., Gardinier M.V. Investigation of myelin/oligodendrocyte glycoprotein membrane topology. J. Neurochem. 67:1996;2219-2222.
8. Adelmann M., Wood J., Benzel I., Fiori P., Lassmann H., Matthieu J.M.et al. The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat. J. Neuroimmunol. 63:1995;17-27.
9. Johns T.G., Kerlero de Rosbo N., Menon K.K., Abo S., Gonzales M.F., Bernard C.C. Myelin oligodendrocyte glycoprotein induces a demyelinating encephalomyelitis resembling multiple sclerosis. J. Immunol. 154:1995;5536-5541.
10. Genain C.P., Abel K., Belmar N., Villinger F., Rosenberg D.P., Linington C.et al. Late complications of immune deviation therapy in a nonhuman primate. Science. 274:1996;2054-2057.
11. Kerlero de Rosbo N., Brok H.P., Bauer J., Kaye J.F., Hart B.A., Ben-Nun A. Rhesus monkeys are highly susceptible to experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein: characterisation of immunodominant T- and B-cell epitopes. J. Neuroimmunol. 110:2000;83-96.
12. Storch M.K., Stefferl A., Brehm U., Weissert R., Wallstrom E., Kerschensteiner M.et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol. 8:1998;681-694.
13. Raine C.S., Cannella B., Hauser S.L., Genain C.P. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Ann. Neurol. 46:1999;144-160.
14. Kerlero de Rosbo N., Honegger P., Lassmann H., Matthieu J.M. Demyelination induced in aggregating brain cell cultures by a monoclonal antibody against myelin/oligodendrocyte glycoprotein. J. Neurochem. 55:1990;583-587.
15. Linington C., Lassmann H. Antibody responses in chronic relapsing experimental allergic encephalomyelitis: correlation of serum demyelinating activity with antibody titre to the myelin/oligodendrocyte glycoprotein (MOG). J. Neuroimmunol. 17:1987;61-69.
16. Schluesener H.J., Sobel R.A., Linington C., Weiner H.L. A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J. Immunol. 139:1987;4016-4021.
17. Linington C., Bradl M., Lassmann H., Brunner C., Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am. J. Pathol. 130:1988;443-454.
18. Sun J., Link H., Olsson T., Xiao B.G., Andersson G., Ekre H.P.et al. T and B cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis. J. Immunol. 146:1991;1490-1495.
19. Kerlero de Rosbo N., Milo R., Lees M.B., Burger D., Bernard C.C., Ben-Nun A. Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. J. Clin. Invest. 92:1993;2602-2608.
20. Wallstrom E., Khademi M., Andersson M., Weissert R., Linington C., Olsson T. Increased reactivity to myelin oligodendrocyte glycoprotein peptides and epitope mapping in HLA DR2(15)+ multiple sclerosis. Eur. J. Immunol. 28:1998;3329-3335.
21. Lindert R.B., Haase C.G., Brehm U., Linington C., Wekerle H., Hohlfeld R. Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein. Brain. 122:1999;2089-2100.
22. Diaz-Villoslada P., Shih A., Shao L., Genain C.P., Hauser S.L. Autoreactivity to myelin antigens: myelin/oligodendrocyte glycoprotein is a prevalent autoantigen. J. Neuroimmunol. 99:1999;36-43.
23. Xiao B.G., Linington C., Link H. Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls. J. Neuroimmunol. 31:1991;91-96.
24. Karni A., Bakimer-Kleiner R., Abramsky O., Ben-Nun A. Elevated levels of antibody to myelin oligodendrocyte glycoprotein is not specific for patients with multiple sclerosis. Arch. Neurol. 56:1999;311-315.
25. Reindl M., Linington C., Brehm U., Egg R., Dilitz E., Deisenhammer F.et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain. 122:1999;2047-2056.
26. Genain C.P., Cannella B., Hauser S.L., Raine C.S. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. 5:1999;170-175.
27. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C.et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13:1983;227-231.
28. Kurtzke J.F. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452.
29. Zajicek J.P., Scolding N.J., Foster O., Rovaris M., Evanson J., Moseley I.F.et al. Central nervous system sarcoidosis - diagnosis and management. Q. J. Med. 92:1999;103-117.
30. Brehm U., Piddlesden S.J., Gardinier M.V., Linington C. Epitope specificity of demyelinating monoclonal autoantibodies directed against the human myelin oligodendrocyte glycoprotein (MOG). J. Neuroimmunol. 97:1999;9-15.
31. Berger T., Reindl M. Immunopathogenic and clinical relevance of antibodies against myelin oligodendrocyte glycoprotein (MOG) in Multiple Sclerosis. J. Neural Transm., Suppl. 60:2000;351-360.
32. Piddlesden S.J., Lassmann H., Zimprich F., Morgan B.P., Linington C. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am. J. Pathol. 143:1993;555-564.
33. Haase C.G., Guggenmos J., Brehm U., Andersson M., Olsson T., Reindl M.et al. The fine specificity of the myelin oligodendrocyte glycoprotein autoantibody response in patients with multiple sclerosis and normal healthy controls. J. Neuroimmunol. 114:2001;220-225.
34. Garcia J.H., Liu K.F., Yoshida Y., Lian J., Chen S., Zoppo G.J. Influx of leukocytes and platelets in an evolving brain infarct (Wistar rat). Am. J. Pathol. 144:1994;188-199.
35. Garcia J.H., Yoshida Y., Chen H., Li Y., Zhang Z.G., Lian J.et al. Progression from ischemic injury to infarct following middle cerebral artery occlusion in the rat. Am. J. Pathol. 142:1993;623-635.
36. Giulian D. Reactive microglia and ischemic injury. Welsh K.M.A., Caplan L.R., Reis D.J., Siesjo B.K., Weir B. Primer on cerebrovascular diseases. 1997;117-124 Academic Press, San Diego.
37. Feuerstein G.Z., Wang X., Barone F.C. Inflammatory mediators and brain injury: the role of cytokines and chemokines in stroke and CNS diseases. Ginsberg M.D., Bogousslavsky J. Cerebrovascular diseases. 1998;507-531 Blackwell, Cambridge.
38. Sharma O.P., Sharma A.M. Sarcoidosis of the nervous system. A clinical approach. Arch. Intern. Med. 151:1991;1317-1321.
39. Zajicek J.P. Nerosrcoidosis. Curr. Opin. Neurol. 13:2000;323-325.
40. Borucki S.J., Nguyen B.V., Ladoulis C.T., McKendall R.R. Cerebrospinal fluid immunoglobulin abnormalities in neurosarcoidosis. Arch. Neurol. 46:1989;270-273.
41. Tsukada N., Yanagisawa N., Mochizuki I. Endothelial cell damage in sarcoidosis and neurosarcoidosis: autoantibodies to endothelial cells. Eur. Neurol. 35:1995;108-112.
42. McLean B.N., Mitchell D.N., Thompson E.J. Local synthesis of specific IgG in the cerebrospinal fluid of patients with neurosarcoidosis detected by antigen immunoblotting using Kveim material. J. Neurol. Sci. 99:1990;165-175.